Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation

Area of Science:

• Neuroimmunology
• Hematology
• Stem Cell Transplantation

Background:

• Multiple sclerosis (MS) is a chronic, demyelinating disease of the central nervous system.
• Current disease-modifying treatments for MS aim to reduce relapse rates and slow disease progression but do not offer a cure.
• Autologous hematopoietic stem cell transplantation (HSCT) is an intensive immunosuppressive therapy with the potential to re-educate the immune system.

Purpose of the Study:

• To evaluate the efficacy of autologous HSCT in achieving sustained complete remission in patients with relapsing-remitting multiple sclerosis (RRMS).
• To assess the long-term outcomes of HSCT in MS patients, including disease activity and resolution markers.

Main Methods:

• A case series of 10 RRMS patients treated with autologous HSCT between 2004 and 2007.
• Patients received either a BEAM/ATG or cyclophosphamide/ATG conditioning regimen followed by stem cell infusion.
• Follow-up was conducted for 10 years, with sustained complete remission defined as "no evidence of disease activity-4" for at least 5 years without disease-modifying treatment.

Main Results:

• Five out of 10 patients (50%) achieved sustained complete remission at the 10-year follow-up.
• In three of these patients, MS was considered resolved, indicated by normalized intrathecal IgG production and cerebrospinal fluid neurofilament light levels.
• No ongoing disease-modifying treatments were required for patients in sustained complete remission.

Conclusions:

• Autologous HSCT can induce sustained complete remission in a significant proportion of patients with relapsing-remitting multiple sclerosis.
• HSCT represents a potential therapeutic option for achieving long-term disease control and resolution in MS.
• Further research is warranted to optimize HSCT protocols and identify patient subgroups most likely to benefit.